David A. Siegel Ardelyx, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ardelyx, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,236,500 shares of ARDX stock, worth $6.53 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,236,500

Previous 594,100 108.13%

Holding current value

$6.53 Million

Previous $2.92 Million 66.16%

% of portfolio

0.01%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$3.28 - $5.51 $2.11 Million - $3.54 Million	642,400 Added 108.13%	1,236,500 $4.85 Million
Q1 2025 May 15, 2025	BUY	$4.91 - $6.36 $1,964 - $2,544	400 Added 0.07%	594,100 $2.92 Million
Q4 2024 Feb 14, 2025	BUY	$4.49 - $6.85 $1.8 Million - $2.74 Million	400,100 Added 206.66%	593,700 $3.07 Million
Q3 2024 Nov 14, 2024	SELL	$5.28 - $7.57 $1.32 Million - $1.89 Million	-250,129 Reduced 56.37%	193,600 $1.33 Million
Q2 2024 Aug 14, 2024	BUY	$5.89 - $9.31 $59,659 - $94,300	10,129 Added 2.34%	443,729 $3.29 Million
Q1 2024 May 15, 2024	BUY	$6.05 - $9.74 $2.62 Million - $4.22 Million	433,600 New	433,600 $3.17 Million
Q2 2023 Aug 14, 2023	SELL	$3.23 - $4.95 $3.99 Million - $6.11 Million	-1,234,500 Reduced 75.79%	394,300 $1.34 Million
Q1 2023 May 15, 2023	BUY	$2.68 - $4.79 $4.37 Million - $7.8 Million	1,628,800 New	1,628,800 $7.8 Million
Q2 2022 Aug 15, 2022	SELL	$0.51 - $1.17 $25,500 - $58,500	-50,000 Reduced 50.56%	48,900 $29,000
Q1 2022 May 16, 2022	BUY	$0.65 - $1.18 $22,685 - $41,182	34,900 Added 54.53%	98,900 $106,000
Q4 2021 Feb 14, 2022	BUY	$0.86 - $1.7 $55,040 - $108,800	64,000 New	64,000 $70,000
Q3 2021 Nov 15, 2021	SELL	$1.27 - $8.17 $341,630 - $2.2 Million	-269,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.55 - $8.98 $2.97 Million - $4.07 Million	-453,000 Reduced 62.74%	269,000 $2.04 Million
Q1 2021 May 17, 2021	BUY	$6.1 - $7.69 $1.22 Million - $1.54 Million	200,000 Added 38.31%	722,000 $4.78 Million
Q4 2020 Feb 16, 2021	SELL	$5.05 - $7.1 $111,100 - $156,200	-22,000 Reduced 4.04%	522,000 $3.38 Million
Q3 2020 Nov 16, 2020	BUY	$5.25 - $7.08 $462,525 - $623,748	88,100 Added 19.32%	544,000 $2.86 Million
Q2 2020 Aug 14, 2020	BUY	$5.37 - $8.11 $1.06 Million - $1.6 Million	197,300 Added 76.3%	455,900 $3.16 Million
Q1 2020 May 15, 2020	BUY	$4.35 - $8.79 $490,679 - $991,511	112,800 Added 77.37%	258,600 $1.47 Million
Q4 2019 Feb 14, 2020	BUY	$4.23 - $8.29 $16,074 - $31,501	3,800 Added 2.68%	145,800 $1.09 Million
Q3 2019 Nov 14, 2019	SELL	$2.15 - $6.28 $7,525 - $21,980	-3,500 Reduced 2.41%	142,000 $667,000
Q2 2019 Aug 14, 2019	SELL	$2.49 - $3.73 $100,596 - $150,692	-40,400 Reduced 21.73%	145,500 $391,000
Q1 2019 May 15, 2019	SELL	$1.88 - $3.35 $110,544 - $196,980	-58,800 Reduced 24.03%	185,900 $521,000
Q4 2018 Feb 14, 2019	SELL	$1.66 - $4.16 $147,242 - $368,992	-88,700 Reduced 26.6%	244,700 $438,000
Q3 2018 Nov 14, 2018	SELL	$3.75 - $4.65 $31,500 - $39,060	-8,400 Reduced 2.46%	333,400 $1.45 Million
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.8 $1.26 Million - $1.98 Million	341,800 New	341,800 $1.27 Million

Others Institutions Holding ARDX

# of Institutions

222

Shares Held

167M

Call Options Held

517K

Put Options Held

1.61M

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $816M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account